Literature DB >> 17041008

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.

Stephanie R Faucette1, Tong-Cun Zhang, Rick Moore, Tatsuya Sueyoshi, Curtis J Omiecinski, Edward L LeCluyse, Masahiko Negishi, Hongbing Wang.   

Abstract

Both the human pregnane X receptor (hPXR) and constitutive androstane receptor (hCAR) are capable of regulating CYP3A4 and CYP2B6 gene expression. However, the majority of currently identified CYP3A4 and CYP2B6 inducers are confirmed activators of hPXR but not hCAR. To compare these receptors with respect to their chemical selectivities, 16 drugs known to induce CYP3A4 and/or CYP2B expression were evaluated for relative activation of hPXR versus hCAR. Because of the high basal but low chemical-induced activation of hCAR in immortalized cells, alternative methods were used to evaluate hCAR activation potential. Thirteen of the 16 compounds were classified as moderate to strong hPXR activators. In contrast, carbamazepine (CMZ), efavirenz (EFV), and nevirapine (NVP) were classified as negligible or weak hPXR activators at concentrations associated with efficacious CYP2B6 reporter or endogenous gene induction in primary human hepatocytes, suggesting potential activation of hCAR. Subsequent experiments demonstrated that these three drugs efficiently induced nuclear accumulation of in vivo-transfected enhanced yellow fluorescent protein-hCAR and significantly increased expression of a CYP2B6 reporter gene when hCAR was expressed in CAR-/- mice. In addition, using a recently identified, chemically responsive splice variant of hCAR (hCAR3), the hCAR activation profiles of the 16 compounds were evaluated. By combining results from the hPXR- and hCAR3-based reporter gene assays, these inducers were classified as hPXR, hCAR, or hPXR/hCAR dual activators. Our results demonstrate that CMZ, EFV, and NVP induce CYP2B6 and CYP3A4 preferentially through hCAR and that hCAR3 represents a sensitive tool for in vitro prediction of chemical-mediated human CAR activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041008      PMCID: PMC4091905          DOI: 10.1124/jpet.106.112136

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene.

Authors:  T Kawamoto; T Sueyoshi; I Zelko; R Moore; K Washburn; M Negishi
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.

Authors:  L B Moore; D J Parks; S A Jones; R K Bledsoe; T G Consler; J B Stimmel; B Goodwin; C Liddle; S G Blanchard; T M Willson; J L Collins; S A Kliewer
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

Review 4.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

5.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

6.  Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3).

Authors:  Scott S Auerbach; Matthew A Stoner; Shengzhong Su; Curtis J Omiecinski
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

Review 7.  Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Authors:  P F Smith; R DiCenzo; G D Morse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

Authors:  Oliver Burk; Katja A Arnold; Andreas K Nussler; Elke Schaeffeler; Ekaterina Efimova; Bonnie A Avery; Mitchell A Avery; Martin F Fromm; Michel Eichelbaum
Journal:  Mol Pharmacol       Date:  2005-03-10       Impact factor: 4.436

9.  Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

Authors:  Jasminder Sahi; Christopher B Black; Geraldine A Hamilton; Xianxian Zheng; Summer Jolley; Kelly A Rose; Darryl Gilbert; Edward L LeCluyse; Michael W Sinz
Journal:  Drug Metab Dispos       Date:  2003-04       Impact factor: 3.922

10.  Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin.

Authors:  Hongbing Wang; Stephanie Faucette; Rick Moore; Tatsuya Sueyoshi; Masahiko Negishi; Edward LeCluyse
Journal:  J Biol Chem       Date:  2004-04-28       Impact factor: 5.157

View more
  121 in total

1.  Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine.

Authors:  Devinder Sharma; Aik Jiang Lau; Matthew A Sherman; Thomas K H Chang
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

2.  Bioactivation of chlorpyrifos by CYP2B6 variants.

Authors:  Alice L Crane; Kathrin Klein; James R Olson
Journal:  Xenobiotica       Date:  2012-07-10       Impact factor: 1.908

3.  Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.

Authors:  Yakun Chen; Yong Tang; Gregory T Robbins; Daotai Nie
Journal:  J Pharmacol Exp Ther       Date:  2010-05-26       Impact factor: 4.030

4.  Genome-wide analysis of human constitutive androstane receptor (CAR) transcriptome in wild-type and CAR-knockout HepaRG cells.

Authors:  Daochuan Li; Bryan Mackowiak; Timothy G Brayman; Michael Mitchell; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Biochem Pharmacol       Date:  2015-08-12       Impact factor: 5.858

5.  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.

Authors:  V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

6.  Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Authors:  Laurence Bousquet; Alain Pruvost; Anne-Cécile Guyot; Robert Farinotti; Aloïse Mabondzo
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

Authors:  Cong Xu; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2013-02-05       Impact factor: 3.614

8.  Human receptor activation by aroclor 1260, a polychlorinated biphenyl mixture.

Authors:  Banrida Wahlang; K Cameron Falkner; Heather B Clair; Laila Al-Eryani; Russell A Prough; J Christopher States; Denise M Coslo; Curtis J Omiecinski; Matthew C Cave
Journal:  Toxicol Sci       Date:  2014-05-08       Impact factor: 4.849

9.  Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice.

Authors:  Junichiro Tohyama; Jeffrey T Billheimer; Ilia V Fuki; George H Rothblat; Daniel J Rader; John S Millar
Journal:  Atherosclerosis       Date:  2008-09-27       Impact factor: 5.162

10.  Influence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes.

Authors:  Brandon Swift; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.